Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

Clinical Cancer Research

Volumn 20, Issue 22, 2014, Pages 5697-5707

  Sanmamed, Miguel F ^a,b   Carranza Rua, Omar ^a   Alfaro, Carlos ^b   Oñate, Carmen ^b   Martín Algarra, Salvador ^a   Perez, Guiomar ^b   Landazuri, Sara F ^a   Gonzalez, Alvaro ^a   Gross, Stefanie ^c   Rodriguez, Inmaculada ^b   Muñoz Calleja, Cecilia ^d   Rodríguez Ruiz, María ^b   Sangro, Bruno ^a,e   López Picazo, José M ^a   Rizzo, Manglio ^f   Mazzolini, Guillermo ^f   Pascual, Juan I ^a   Andueza, Maria Pilar ^a   Perez Gracia, Jose Luis ^a   Melero, Ignacio ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f UNIVERSIDAD AUSTRAL   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 8; IPILIMUMAB; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; BLOOD; DISEASE MODEL; DRUG SCREENING; KNOCKOUT MOUSE; MORTALITY; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-8; MICE, KNOCKOUT; NEOPLASMS; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918550680     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3203     Document Type: Article

References (57)

1. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001;12:375-91.
2. Yuan A, Chen JJW, Yao P-L, Yang P-C. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 2005;10:853-65.
3. Walz A, Peveri P, Aschauer H, Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun 1987;149:755-61.
4. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989;84:1045-9.
5. Waugh DJJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-41.
6. Kotyza J. Interleukin-8 (CXCL8) in tumor associated non-vascular extracellular fluids: its diagnostic and prognostic values. A review. Int J Biol Markers 2012;27:169-78.
7. Infanger DW, Cho Y, Lopez BS, Mohanan S, Liu SC, Gursel D, et al. Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Cancer Res 2013;73:7079-89.
8. Singh JK, Simões BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res 2013;15:210.
9. Roebuck KA. Regulation of interleukin-8 gene expression. J Interferon Cytokine Res 1999;19:429-38.
10. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 2011;41:2522-5.
11. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69:1553-60.
12. Alfaro C, Suárez N, Martínez-Forero I. Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS ONE 2011;6:e17922.
13. Schadendorf D, Möller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993;151:2667-75.
14. Scheibenbogen C, Möhler T, Haefele J, Hunstein W, Keilholz U. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 1995;5:179-81.
15. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007;13:2422-8.
16. Orditura M, De Vita F, Catalano G, Infusino S, Lieto E, Martinelli E, et al. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 2002;22:1129-35.
17. Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. Br J Cancer 2012;106:1153-9.
18. Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GLJ, et al. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 1999;53:139-47.
19. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Konieczny D, et al. Elevation of circulating interleukin-8 is related to lymph node and distant metastases in esophageal squamous cell carcinomas - implication for clinical evaluation of cancer patient. Cytokine 2008;41:232-9.
20. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer 2002;100:463-71.
21. Rutkowski P, Kamins̈ka J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003;84:151-9.
22. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin A-M, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012;13:827-37.
23. Sheryka E, Wheeler MA, Hausladen DA, Weiss RM. Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 2003;62:162-6.
24. Bellmunt J, Gonzalez-Larriba J. First-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential. Ann Oncol 2011;22:2646-53.
25. Ren Y, Poon RT-P, Tsui H-T, Chen W-H, Li Z, Lau C, et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res 2003;9:5996-6001.
26. Welling TH, Fu S, Wan S, Zou W, Marrero JA. Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival. Cancer Invest 2012;30:689-97.
27. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 1994;29:423-9.
28. Konno H, Ohta M, Baba M, Suzuki S, Nakamura S. The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci 2003;94:735-40.
29. Chen Y, Shi M, Yu G, Qin X. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol 2012;18:1123-9.
30. Ivarsson K, Runesson E, Sundfeldt K. The chemotactic cytokine interleukin-8 - a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncol 1998;71:420-3.
31. Benoy I, Salgado R, Van Dam P. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157-62.
32. Samaras V, Piperi C, Levidou G, Zisakis A, Kavantzas N, Themistocleous MS, et al. Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum Immunol 2009;70:391-7.
33. Nacinović-Duletić A, Stifter S, Dvornik S, Skunca Z, Jonjić N. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol 2008;30:230-9.
34. Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, et al. Prognostic signi ficance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res 2013;19:6812-9.
35. Zarogoulidis P, Katsikogianni F, Tsiouda T, Sakkas A, Katsikogiannis N, Zarogoulidis K. Interleukin-8 and interleukin-17 for cancer. Cancer Invest 2014;32:197-205.
36. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant. J Thorac Oncol 2007;2:706-14.
37. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
38. Hoffmann E. Multiple control of interleukin-8 gene expression. J Leukoc Biol 2002;72:847-55.
39. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994;55:97-179.
40. Harada A, Sekido N. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 1994;56:559-64.
41. Makarem M El. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon 2012;12:e6122.
42. Gioulbasanis I, Patrikidou A. Baseline plasma levels of interleukin-8 in stage IV non- small-cell lung cancer patients: relationship with nutritional status and prognosis. Nutr Cancer 2012;64:41-7.
43. Hao W, Zhu Y, Zhou H. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer. Med Oncol 2013;30:333.
44. Sunaga N, Kaira K, Tomizawa Y, Shimizu K, Imai H, Takahashi G, et al. Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. Br J Cancer 2014;110:2047-53.
45. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derivedmediator of angiogenesis. Science 1992;258:1798-801.
46. Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, et al. Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res 2006;16:317-23.
47. Visconti L, Nelissen K, Deckx L, van den Akker M, Adriaensen W, Daniels L, et al. Prognostic value of circulating cytokines on overall survival and disease-free survival in cancer patients. Biomark Med 2014;8:297-306.
48. Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, et al. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 2000;6:790-7.
49. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 2006;24:492-6.
50. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
51. Merchant TE, Li C, Xiong X, Gaber MW. Cytokine and growth factor responses after radiotherapy for localized ependymoma. Int J Radiat Oncol Biol Phys 2009;74:159-67.
52. Brennecke S, Deichmann M, Naeher H, Kurzen H. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 2005;15:515-22.
53. Zakrzewska I, Omyøa J. [The value of plasma interleukin-6 and interleukin-8 in monitoring of patients with breast cancer]. Pol Merkur Lekarski 2005;18:424-6.
54. Frederick D, Piris A, Cogdill A. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19:1225-31.
55. Koc¸ak H, Oner-Iyidoʇan Y, Koc¸ak T, Oner P. Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer. Clin Biochem 2004;37:673-8.
56. Thalmann GN, Dewald B, Baggiolini M, Studer UE. Interleukin-8 expression in the urine after Bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol 1997;158:1340-4.
57. Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with Bacillus Calmette-Guerin. J Urol 2000;164:2129-33.